Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
The Role of Nuclear Medicine in Cancer Diagnosis and Therapy
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

The Role of Nuclear Medicine in Cancer Diagnosis and Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 August 2024 | Viewed by 935

Special Issue Editor

Dr. Masato Kobayashi

E-Mail Website
Guest Editor
Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan
Interests: PET; SPECT; multimodality; imaging analysis; pharmacokinetics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nuclear Medicine with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is an important tool for the diagnosis of various diseases and the radionuclide therapy of cancers. It also has translational potential, from preclinical to clinical studies, in personalized medicine for many diseases. Multimodal imaging and/or therapy including nuclear medicine, magnetic resonance imaging, ultrasonography, near-infrared imaging, etc., may create further progress in personalized medicine. In addition, advanced PET and SPECT imaging technologies emphasize the usefulness of nuclear medicine.

This Special Issue focuses on the synthesis and evaluation of novel radiopharmaceuticals, the other applications of radiopharmaceuticals for clinical use, and the combination of radionuclides with other imaging modalities. Advanced PET and SPECT scanners and imaging technologies are also target topics. However, the areas of interest are not limited to these keywords. This Special Issue will focus on fundamental cellular/molecular studies, and papers that contain only clinical trials/data will not be accepted.

Dr. Masato Kobayashi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PET
  • SPECT
  • diagnosis
  • radionuclide therapy
  • theranostics
  • radiopharmaceutical
  • pharmakinetic
  • multimodality
  • imaging technology
  • disease

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2191 KiB  
Article
Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion
by Sergey M. Deyev, Maryam Oroujeni, Javad Garousi, Torbjörn Gräslund, Ruonan Li, Alia Hani Binti Rosly, Anna Orlova, Elena Konovalova, Alexey Schulga, Anzhelika Vorobyeva and Vladimir Tolmachev
Int. J. Mol. Sci. 2024, 25(8), 4246; https://doi.org/10.3390/ijms25084246 - 11 Apr 2024
Viewed by 771
Abstract
Designed ankyrin repeat protein (DARPin) G3 is an engineered scaffold protein. This small (14.5 kDa) targeting protein binds with high affinity to human epidermal growth factor receptor 2 (HER2). HER2 is overexpressed in several cancers. The use of the DARPin G3 for radionuclide [...] Read more.
Designed ankyrin repeat protein (DARPin) G3 is an engineered scaffold protein. This small (14.5 kDa) targeting protein binds with high affinity to human epidermal growth factor receptor 2 (HER2). HER2 is overexpressed in several cancers. The use of the DARPin G3 for radionuclide therapy is complicated by its high renal reabsorption after clearance via the glomeruli. We tested the hypothesis that a fusion of the DARPin G3 with an albumin-binding domain (ABD) would prevent rapid renal excretion and high renal reabsorption resulting in better tumour targeting. Two fusion proteins were produced, one with the ABD at the C-terminus (G3-ABD) and another at the N-terminus (ABD-G3). Both variants were labelled with 177Lu. The binding properties of the novel constructs were evaluated in vitro and their biodistribution was compared in mice with implanted human HER2-expressing tumours. Fusion with the ABD increased the retention time of both constructs in blood compared with the non-ABD-fused control. The effect of fusion with the ABD depended strongly on the order of the domains in the constructs, resulting in appreciably better targeting properties of [177Lu]Lu-G3-ABD. Our data suggest that the order of domains is critical for the design of targeting constructs based on scaffold proteins. Full article
(This article belongs to the Special Issue The Role of Nuclear Medicine in Cancer Diagnosis and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop